Amlodipine for Myocardial Iron in Thalassemia

Inclusion Criteria: * Pediatric patients aged ≥ 6 and ≤ 20 years managed at AKUH for at least 1 year * ≥ 10 blood transfusion in life time * Transfusion need ≥ 180 ml/kg/year * Serum ferritin ≥ 1000 ug/dl * Patient deemed capable of receiving chelation therapy (by treating hematologist) either subcutaneous infusion of Deferoxamine (Desferal) (3-5 days a week) or oral deferasirox (daily) or Defeperione (oral) or a combination of Desferal and Defeperione. * Patients who have been on a stable chelation regimen ≥ 6 months * Completed and signed Informed consent/assent. Exclusion Criteria: * Patients with known hypersensitivity to amlodipine. * Patients with known sinoatrial nodal disease or aortic stenosis. * Patients with known severe myocardial dysfunction, defined as A LV ejection fraction of ≤ 4 SD for age even without symptoms. * Patients with known signs and symptoms of heart failure. * Patients with a T2\* value of \< 4 ms on cardiac MRI. * Patients with systolic blood pressures ≤ 2 SD for age (systemic hypotension) at the time of enrolment. * Patients with previously diagnosed significant congenital heart diseases or acquired heart diseases other than thalassemia (as defined earlier). * Patients with known contraindications to MRI (pacemakers, cerebral aneurysm metal clips, etc.) * Patient with a known history of developing tetany after use of a calcium channel blocker * Known pregnancy.